Palfi, S., Gurruchaga, J., Ralph, G., Lepetit, H., Lavisse, S., Buttery, P., Watts, C., Miskin, J., Kelleher, M., Deeley, S., Iwamuro, H., Lefaucheur, J., Thiriez, C., Fenelon, G., Lucas, C., Brugières, P., Gabriel, I., Abhay, K., Drouot, X., Tani, N., Kas, A., Ghaleh, B., Le Corvoisier, P., Dolphin, P., Breen, D., Mason, S., Guzman, N., Mazarakis, N., Radcliffe, P., Harrop, R., Kingsman, S., Rascol, O., Naylor, S., Barker, R., Hantraye, P., Remy, P., Cesaro, P. & Mitrophanous, K. (2014). Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet (London, England), 383(9923), 1138-46. doi:10.1016/S0140-6736(13)61939-X